Clinical Trial Update: A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients [Phase 4]

View source ↗

Summary

Phase 4, open-label, non-randomized clinical trial evaluating whether natalizumab improves ambulatory measures in relapsing-remitting multiple sclerosis; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 4 | Status: COMPLETED | Results posted: 2014-11-18